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Abstract
Background: Johanson-Blizzard syndrome (JBS; OMIM 243800) is an autosomal recessive disorder that includes congenital
exocrine pancreatic insufficiency, facial dysmorphism with the characteristic nasal wing hypoplasia, multiple malformations,
and frequent mental retardation. Our previous work has shown that JBS is caused by mutations in human UBR1, which
encodes one of the E3 ubiquitin ligases of the N-end rule pathway. The N-end rule relates the regulation of the in vivo half-
life of a protein to the identity of its N-terminal residue. One class of degradation signals (degrons) recognized by UBR1 are
destabilizing N-terminal residues of protein substrates.
Methodology/Principal Findings: Most JBS-causing alterations of UBR1 are nonsense, frameshift or splice-site mutations
that abolish UBR1 activity. We report here missense mutations of human UBR1 in patients with milder variants of JBS. These
single-residue changes, including a previously reported missense mutation, involve positions in the RING-H2 and UBR
domains of UBR1 that are conserved among eukaryotes. Taking advantage of this conservation, we constructed alleles of
the yeast Saccharomyces cerevisiae UBR1 that were counterparts of missense JBS-UBR1 alleles. Among these yeast Ubr1
mutants, one of them (H160R) was inactive in yeast-based activity assays, the other one (Q1224E) had a detectable but weak
activity, and the third one (V146L) exhibited a decreased but significant activity, in agreement with manifestations of JBS in
the corresponding JBS patients.
Conclusions/Significance: These results, made possible by modeling defects of a human ubiquitin ligase in its yeast
counterpart, verified and confirmed the relevance of specific missense UBR1 alleles to JBS, and suggested that a residual
activity of a missense allele is causally associated with milder variants of JBS.
Citation: Hwang C-S, Sukalo M, Batygin O, Addor M-C, Brunner H, et al. (2011) Ubiquitin Ligases of the N-End Rule Pathway: Assessment of Mutations in UBR1
That Cause the Johanson-Blizzard Syndrome. PLoS ONE 6(9): e24925. doi:10.1371/journal.pone.0024925
Editor: Alfred Nordheim, University of Tuebingen, Germany
Received July 26, 2011; Accepted August 19, 2011; Published September 13, 2011
Copyright:  2011 Hwang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the German Research Foundation (DFG) grant ZE 5242-3 to M.Z. and grant MA 4115/1-3 to J.M.; by the Korea Research
Foundation grant 2008-313-C00521 to H.K.S.; by a grant from the March of Dimes Foundation to A.V.; and by the National Institutes of Health (NIH) grants
GM031530 and DK039520 to A.V. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: avarsh@caltech.edu (AV); martin.zenker@med.ovgu.de (MZ)
¤ Current address: Department of Life Science, Pohang University of Science and Technology, Pohang, South Korea
Introduction
Johanson-Blizzard syndrome (JBS; OMIM 243800) is a rare
autosomal recessive genetic disease of multiple congenital
malformations. A combination of nasal wing aplasia and exocrine
pancreatic insufficiency is particularly characteristic of JBS. Other
commonly encountered JBS features include short stature,
oligodontia, deafness, scalp defects, hypothyroidism, imperforate
anus, genitourinary malformations, and frequent mental retarda-
tion [1–5]. Our previous work [6] and subsequent studies [7–9]
have shown that JBS results from homozygous or compound
heterozygous mutations in human UBR1, which encodes one of
the E3 ubiquitin (Ub) ligases of the N-end rule pathway [10,11].
We also found an exocrine pancreatic insufficiency in Ubr1
2/2
mice that lacked Ubr1, a phenotype similar to but less severe than
the pancreatic phenotype of JBS patients that apparently lack
active UBR1 [6].
The N-end rule relates the regulation of the in vivo half-life of an
intracellular protein to the identity of its N-terminal residue
[12–20]. In eukaryotes, the N-end rule pathway is a part of the Ub
system, which mediates protein turnover through the conjugation
of Ub, a 76-residue protein, to proteins that contain specific
degradation signals (degrons), thereby marking these proteins for
degradation by the 26S proteasome [16,17,21–27]. N-terminal
degrons recognized by the N-end rule pathway are called N-
degrons. The main determinant of an N-degron is a destabilizing
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24925N-terminal residue of a protein (Fig. 1A). Recognition components
of the N-end rule pathway are called N-recognins. In eukaryotes,
N-recognins are E3 Ub ligases that bind to specific N-degrons
[11,15–17,28–34].
The N-end rule pathway consists of two branches, the Ac/N-end
rule and the Arg/N-end rule pathways. The Ac/N-end rule
pathway targets proteins containing N
a-terminally acetylated (Nt-
acetylated) residues [17,32]. It involves the cotranslational Nt-
acetylation of nascent proteins [35–43] whose N-termini bear either
Met or the small uncharged residues Ala, Val, Ser, Thr or Cys. The
Arg/N-end rule pathway involves the N-terminal arginylation (Nt-
arginylation) of protein substrates and also the targeting of
unacetylated destabilizing N-terminal residues (including Arg) by
specific E3 N-recognins that contain the evolutionary conserved
UBR domain (Fig. 1A) [16,17,20,27,28,33,44–49]. The ‘primary’
destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, Tyr, Trp,
and Ile aredirectly recognized by E3 N-recognins of the Arg/N-end
rule pathway, whereas N-terminal Asp, Glu, Asn, Gln, and Cys
function as destabilizing residues through their preliminary
modifications. These modifications include Nt-arginylation by the
Ate1 arginyl-transferase (R-transferase) (Fig. 1A) [17,46,47,50,51].
Regulated degradation of specific proteins by the Arg/N-end
rule pathway mediates a legion of physiological functions,
including the sensing of heme, nitric oxide (NO), oxygen and
Figure 1. The mammalian Arg/N-end rule pathway and missense mutations in human UBR1 that underlie specific cases of the
Johanson-Blizzard syndrome (JBS). (A) The mammalian N-end rule pathway. N-terminal residues are indicated by single-letter abbreviations for
amino acids. Yellow ovals denote the rest of a protein substrate. ‘Primary’, ‘secondary’ and ‘tertiary’ denote mechanistically distinct subsets of
destabilizing N-terminal residues (see Introduction). C* denotes oxidized Cys, either Cys-sulfinate or Cys-sulfonate. MetAPs, Met-aminopeptidases. (B)
Single-residue mutations in the UBR1 proteins of JBS patients #1 and #2. The positions of mutant residues are indicated both for the original
mutations in human UBR1 and for their mimics in S. cerevisiae. (C) Same as in B but the mutation in UBR1 of patient #3 (see Results).
doi:10.1371/journal.pone.0024925.g001
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regulation of DNA repair and cohesion/segregation of chromo-
somes; the signaling by G proteins; the regulation of peptide
import, meiosis, apoptosis, viral and bacterial infections, fat
metabolism, cell migration, actin filaments, spermatogenesis,
neurogenesis, and cardiovascular development; the functioning
of adult organs, including the brain, muscle, testis and pancreas;
and the regulation of leaf, shoot and seed development in plants
(refs. [15–19,27,32,46,47,50,51–53] and refs. therein).
In the yeast Saccharomyces cerevisiae, the Arg/N-end rule pathway
is mediated by the RING-type Ubr1 E3 Ub ligase. The type-1 and
type-2 substrate-binding sites of Ubr1 recognize the unmodified
basic (Arg, Lys, His) and bulky hydrophobic (Leu, Phe, Tyr, Trp,
Ile) N-terminal residues, respectively [16,17,28,30,33]. The type-1
binding site of Ubr1 resides in the ,70-residue UBR domain
[16,54] that has been solved at atomic resolution [20,48,49]. In
addition to its type-1/2 binding sites, Ubr1 contains substrate-
binding sites that recognize internal (non-N-terminal) degrons of
proteins that include Cup9, Mgt1, and misfolded proteins
[44,52,55–60]. Recent work showed that the Ubr1-based targeting
ensemble is a physical complex of the RING-type Ubr1 E3 and
the HECT-type Ufd4 E3, together with their cognate E2 enzymes
[26,27,56]. N-recognins of the mammalian Arg/N-end rule
pathway comprise at least four E3 Ub ligases, UBR1, UBR2,
UBR4 and UBR5, all of which contain a UBR domain
[11,17,18,20,28,34,48,49,54,61,62]. The 200 kDa mammalian
UBR1 and UBR2 are highly sequelogous (similar in sequence
[63]) to each other and to the 225 kDa S. cerevisiae Ubr1, but are
largely nonsequelogous (outside of their UBR domains) to other N-
recognins such as UBR4 and UBR5.
Given the multiplicity and a partial functional redundancy of
mammalian N-recognins, including the sequelogous UBR1 and
UBR2 [18,34,64], the Arg/N-end rule pathway is still present (at a
lower level of activity) in either JBS patients or Ubr1
2/2 mice
[6,11]. Most of the known JBS-causing changes of human UBR1
are nonsense, frameshift or splice-site mutations that are either
certain or very likely to completely abolish UBR1 activity [6]. We
report here novel single-residue changes of UBR1 in patients with
milder variants of JBS. These changes and one previously reported
missense mutation involve amino acid residues that are conserved
between the 200-kDa human UBR1 and the 225-kDa S. cerevisiae
Ubr1 (Fig. 1B, C). Taking advantage of this evolutionary
conservation, we constructed alleles of S. cerevisiae UBR1 that were
counterparts of missense UBR1 alleles, and examined the resulting
Ubr1 proteins for their activity in the S. cerevisiae Arg/N-end rule
pathway.
Results
Clinical findings
Clinical characteristics of three patients whose UBR1 mutations
were analyzed in this study are summarized in Table 1. All
patients represented sporadic cases and were born to healthy
unrelated parents of European origin. Patient #1 was a 17 year
old female with congenital pancreatic insufficiency and subtle
facial signs of JBS (Fig. 2A). She had a small scalp defect at birth
and developed mild sensorineural deafness (,30 dB) requiring no
hearing aids so far. This patient exhibited mild developmental
delay and learning difficulties. She has completed a secondary
school with support and is involved in a vocational training
program to become ‘health assistant’. Based on her relatively high
(for a JBS patient) mental status and moderate JBS-type physical
and physiological anomalies, she was classified as having a mild
form of JBS.
Patient #2 was a 14 year old female with a typical clinical
picture of severe JBS (Fig. 2B; cf. Fig. 2D). Her genotype has been
reported previously [6] (Fig. 1B). In addition to the typical nasal
wing aplasia and congenital pancreatic insufficiency, patient #2
also exhibited scalp defects, anal atresia, renal anomalies,
hypothyroidism, severe deafness, oligodontia, and short stature.
Her cognitive performance was in the mentally retarded range (IQ
50–60).
Patient #3 was a 10 year old girl who was diagnosed with mild
JBS, based on the presence of pancreatic insufficiency and mild
facial anomalies (Fig. 2C). She was born with a small scalp defect
at the vertex and has been wearing hearing aids since she was 4
years old. Many permanent teeth are missing. The girl is attending
a special school for children with hearing impairments. Her
cognitive level is reported to be in the low normal range. No
formal IQ testing has been done so far.
Table 1. Clinical features in JBS patients.
Patient Patient #1 Patient #2 Patient #3
Genotype
p.V122L
p.H774SfsX5
p.H136R
c.2254+2T.C
p.Q1102E
p.R503X
Total
(n=58)
a
Biallelic nonsense/
frameshift mutations
(n=12)
b
Pancreatic insufficiency +++ 49/50 (98%) 12/12 (100%)
Dental defects +++ 27/28 (96%) 6/6 (100%)
Nasal wing hypoplasia very mild + mild 54/55 (98%) 12/12 (100%)
Deafness mild ++ 31/45 (69%) 10/11 (91%)
Scalp defect +++ 41/57 (72%) 8/12 (67%)
Hypothyroidism - + - 17/46 (37%) 5/10 (50%)
Short stature - + - 32/38 (84%) 8/9 (89%)
Urogenital anomalies - + - 15/51 (29%) 5/12 (42%)
Imperforate anus - + - 20/58 (34%) 6/12 (50%)
Mental retardation - + - 25/36 (69%) 8/8 (100%)
aRef. 1;
bRef. 6 and unpublished data.
doi:10.1371/journal.pone.0024925.t001
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Patients #1–3 were compound UBR1 heterozygotes. Specifi-
cally, each of them carried a missense mutation in one UBR1 allele
and a mutation in the other UBR1 allele that would be, most likely,
a null mutation. Patient #1 was compound heterozygous for the
missense mutation c.364G.C (p.V122L) in exon 3 (Fig. 1B) and a
1 bp duplication (c.2319dupT) in exon 21. The latter UBR1
mutation resulted in a translational frameshift and a premature
stop codon (p.H774SfsX5). Patient #2 was compound heterozy-
gous for the exon 3 missense mutation c.407A.G (p.H136R) in
exon 3 (Fig. 1B) and a mutation at the splice donor site of exon 20
(c.2254+2T.C). The latter mutation is predicted to cause a
skipping of the 64-bp exon 20, resulting in a shift of the UBR1
open reading frame (ORF) and premature stop codon (Mutation
Taster: www.mutationtaster.org/). Patient #3 carried a missense
mutation c.3304C.G (p.Q1102E) in exon 30 of one UBR1 allele
(Fig. 1C) and a nonsense mutation c.1507C.T (p.R503X) in exon
13 of the other allele.
A preferential expression of the corresponding missense UBR1
alleles was observed with patients #1 and #3, whose blood
leukocyte RNA samples were available (data not shown),
consistent with the (presumed) nonsense-mediated decay (NMD)
of mutant UBR1 mRNAs that were transcribed from the UBR1
alleles containing the frameshift and nonsense mutations in
patients #1 and #3, respectively. Among the three missense
alleles of UBR1, two of them, V122L (patient #1) and Q1102E
(patient #3), are novel (Fig. 1B, C). The H136R mutation in
UBR1 of patient #2 was described by us previously [6]. None of
these UBR1 mutations were found in more than 300 healthy
control subjects. The three affected positions in UBR1 proteins of
patients #1–3 are sufficiently highly conserved to have unambig-
uously identifiable counterparts in S. cerevisiae Ubr1 and in other
eukaryotes as well (Fig. 1B, C).
The V122L mutation in patient #1 and the H136R mutation in
patient #2 are located in the N-terminus-proximal UBR box of
human UBR1 (and S. cerevisiae Ubr1), whereas the Q1102E
mutation affects the RING-H2 domain in the C-terminal half of
Ubr1 (Figs. 1B, C and 3A). Positions 122, 136 and 1,102 of the
human UBR1 protein correspond to positions 146, 160, and 1,224
of S. cerevisiae Ubr1 (Fig. 1B, C). Fig. 3A, B illustrates the overall
organization of the 225 kDa S. cerevisiae Ubr1 and the structure of
its UBR domain [48]. This crystal-derived structure of UBR in
yeast Ubr1 is highly spalogous (spatially similar [63]) to the crystal
structure of the human UBR domain [20,49]. Fig. 3B–D
illustrates, through molecular modeling, the spatial configurations
of locales in the structure of the UBR domain that contain single-
residue JBS alterations. These models were produced by mutating
specific residues of wild-type UBR1 in silico and thereafter choosing
rotamers of these residues to minimize steric clashes (Fig. 3C, D).
The wild-type Val
146 residue of yeast Ubr1 (Val
122 in human
UBR1) is located immediately before a short b-strand that forms in
the UBR domain upon its binding to a peptide with N-terminal Arg
(a mimic of N-end rule substrate) (Fig. 3B). This region of the UBR
domain exists as a loop in the absence of a bound peptide [48].
Because the side chain of Leu is larger than that of Val, the V146L
alteration of Ubr1 (Fig. 1B) is expected to locally perturb UBR
conformation, but not in a major way. In Fig. 3C, the second
residue of the UBR-bound peptide is Leu, denoted as ‘Leu2s’, i.e.,
Leu
2 of substrate. One testable possibility is that the V146L
mutationdecreasestheaffinityoftheUBRdomainfortype-1N-end
rule substrates with position-2 residues that are bulkier than Leu.
As to the H160R mutation, i.e. the other missense JBS
alteration in the UBR domain, (H136R in human UBR1), its
likely functional consequences are more clear and more severe,
because wild-type His
160 is one of two histidines and two cysteines
that coordinate Zn3, a third zinc ion in the UBR domain (Fig. 3B,
D). A bulky and strongly positively charged residue such as Arg at
this position is likely to destabilize coordination of Zn3 (Fig. 3D). In
contrast to the wild-type Ubr1, Ubr1
V146L and Ubr1
Q1224E
proteins, Ubr1
H160R was expressed at low steady-state levels both
in S. cerevisiae and in lymphocytes of patient #2, strongly suggesting
itsmetabolicinstability(seebelow).Finally,althougha 3-Dstructure
ofthe RING-H2domain, intheC-terminalhalf ofUbr1(Fig.3A),is
unknown, it is likely that the replacement of the highly conserved
uncharged Gln
1224 (Gln
1102 in human UBR1) by the charged Glu
residue in Ubr1
Q1224E (Fig. 1C) would significantly perturb RING-
H2(aZn-stabilized domain inRING-typeE3Ub ligases [24,65,66].
The function of the RING-H2 domain in Ubr1 includes the
interaction ofthis E3withacognateE2enzyme(Rad6inS.cerevisiae,
HR6A or HR6B in mammals) [11,17,34,67,68].
Functional testing of S. cerevisiae JBS-type Ubr1 mutants
Low-copy (CEN-based) plasmids that expressed the wild-type S.
cerevisiae Ubr1 and its single-residue mutants Ubr1
V146L,
Ubr1
H160R and Ubr1
Q1224E (Fig. 1B, C) from the native yeast
PUBR1 promoter, were transformed into ubr1D cells that lacked
Ubr1 and therefore lacked the Arg/N-end rule pathway. These
cells also carried plasmids that expressed the previously charac-
terized X-b-galactosidase (X-bgal) N-end rule reporters, produced
using the Ub fusion technique, i.e. through the cotranslational
deubiquitylation, by a family of deubiquitylase enzymes, of Ub-X-
bgal fusion proteins (X=His, Tyr) [27,30–32,69]. The His and
Figure 2. JBS patients. (A) Patient #1, whose facial appearance is
nearly normal. Note the frontal upsweep of the hair and subtle
hypoplasia of the nasal wings (minor signs of JBS). (B) Patient #2, a
typical facial appearance of JBS, including the aplasia of nasal wings,
midface hypoplasia, and a characteristic frontal hair pattern. (C) Patient
#3, with a mild hypoplasia of nasal wings. (D) A previously described
case of severe JBS, with typical facial features, in which both alleles of
UBR1 were, most likely, null alleles (see Results and ref. [6]).
doi:10.1371/journal.pone.0024925.g002
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and type-2 primary destabilizing N-terminal residues (Fig. 1A).
These residues are recognized by the corresponding binding sites
of Ubr1 (see Introduction). As shown previously, the enzymatic
activity of bgal in extracts from yeast cells that express an X-bgal
reporter can serve as a reliable measure of the reporter’s metabolic
stability [30,31,69]. We chose His and Tyr as the N-terminal
residues of X-bgal reporters for these assays, instead of, for
example, the more ‘destabilizing’ type-1 and type-2 N-terminal
residues such as Arg or Leu. The moderately destabilizing His
(type-1) and Tyr (type-2) residues resulted in a slower degradation
of the corresponding N-end rule reporters in wild-type cells,
thereby increasing the sensitivity of this assay to changes in Ubr1
activity.
Steady-state levels of His-bgal and Tyr-bgal were significantly
decreased in cells that expressed wild-type Ubr1, in comparison to
Figure 3. S. cerevisiae Ubr1 N-recognin. (A) A diagram of the 225 kDa S. cerevisiae Ubr1. The indicated evolutionarily conserved regions of Ubr1
are the UBR box, the BRR (basic residues-rich) domain, the Cys/His-rich RING-H2 domain, and the AI (autoinhibitory) domain [18,30,33]. Three
missense mutations in patients #1-3 of the present work are indicated as well (see Fig. 1B, C). (B) Ribbon diagram of the S. cerevisiae UBR domain [48]
in a complex with RLGES, the N-terminal region of the separase-produced fragment of Scc1, a subunit of cohesin [75]. The bound RLGES peptide is
shown as a stick model, with carbon atoms colored yellow. Several residues are marked with a black sphere and numbered to facilitate the tracing of
the polypeptide chain. The names of residues of the RLGES peptide are in red, with the letter ‘s’ (substrate) appended to their position numbers. Side-
chains of residues in the UBR domain that are present near JBS mutations (Fig. 1B, C) are shown in a stick form, with carbon atoms colored green.
Three coordinated zinc ions of the UBR domain [48] are shown as red spheres. (C) Close-up view of the UBR region near the V146L mutation (patient
#1; Fig. 1B). In panel B, this region of UBR is boxed and labeled as ‘C’. The residues of UBR that accommodate the position-2 Leu residue (‘Leu2s’) of
the RLGES peptide substrate are shown and labeled. The van der Waals sphere of the mutant Leu residue, in the UBR1
V146L mutant, is shown as
purple dots. (D) Close-up view of the UBR region near the H160R mutation (patient #2, Fig. 1B). In panel B, this region of UBR is boxed and labeled as
‘D’. The residues of UBR coordinating Zn3 atom are shown and labeled. The van der Waals sphere of the mutant Arg residue, in the UBR1
H160R
mutant, is shown as purple dots. The views in (C) and (D) are oriented to maximize visibility of mutation-proximal residues.
doi:10.1371/journal.pone.0024925.g003
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by the Arg/N-end rule pathway [27,30,31,69] (Fig. 4A).
Ubr1
H160R, whose single-residue mutation resides in the UBR
domain, in the region of the Zn3 ion coordination that is expected
to be strongly perturbed by the change from His to Arg at position
160 (Figs. 1B, 3D, and discussion above), was completely inactive
in conferring metabolic instability on His-bgal or Tyr-bgal
(Fig. 4A). The absence of detectable activity in Ubr1
H160R resulted,
most likely, from the above structural perturbation but could be also
caused, in part, by the metabolic instability of Ubr1
H160R (see
below). The same measurements with Ubr1
Q1224E, whose single-
residue mutation resides in the RING-H2 domain (Figs. 1B, C and
3A) indicated a much lower than wide-type but reproducibly
detectable activity of Ubr1
Q1224E toward both His-bgal and
Figure 4. Functional activity of yeast Ubr1 mimics of missense JBS-UBR1 mutants. (A) Relative enzymatic activity of bgal in extracts from S.
cerevisiae JD55 (ubr1D) that expressed His-bgal or Tyr-bgal, and also carried an empty vector, or an otherwise identical plasmid expressing wild-type
S. cerevisiae Ubr1, or (separately) its three missense mutants Ubr1
V146L, Ubr1
H160R, or Ubr1
Q1224E. The activity of bgal was measured in triplicates, with
standard deviations shown. (B) Relative levels of induction of the peptide transporter Ptr2 were assayed by measuring the activity of a plasmid-borne
lacZ (bgal-encoding) reporter that was expressed from the PPTR2 promoter in ubr1D S. cerevisiae that carried either an empty vector or otherwise
identical plasmids that expressed either wild-type Ubr1 [27,28,52] or its indicated mutants. Cells were grown to A600 of ,0.8 in SC(-Ura, -Leu) medium
at 30uC, followed by measurements, in triplicate, of bgal activity in cell extracts, with standard deviations shown. (C) The lysine-requiring JD55 (ubr1D)
S. cerevisiae strain was grown on plates containing 110 mM lysine (Lys) or 66 mM Lys-Ala dipeptide as the sole source of Lys in the medium [27,33,52].
JD52 (ubr1D) cells carried a vector plasmid or otherwise identical plasmids expressing wild-type Ubr1 or its missense mutants Ubr1
H160R, Ubr1
V146L
and Ubr1
Q1224E. Cells were grown to A600 of ,1 in SC(-Leu) medium at 30uC, washed in sterile water, serially diluted 5-fold, spotted on SC(-Leu, -Lys)
plates containing 110 mM Lys or 66 mM Lys-Ala, and incubated at 30uC for 3 days. (D) Cell extracts (equal total protein levels) from experiments
described in panels A and B were subjected to SDS-PAGE, followed by immunoblotting with affinity-purified anti-Ubr1 antibody (upper panel) and
anti-tubulin antibody (a loading control; lower panel). Asterisk indicates a protein that crossreacts with anti-Ubr1 antibody. (E) Extracts from human
lymphocytes (equal amounts of total protein) were subjected to SDS-PAGE, followed by immunoblotting with antibody to human UBR1 (see
Materials and Methods). Lane 1, wild-type lymphocytes. Lane 2, same as lane 1 but from lymphocytes of patient #2 (see the main text and Figs. 1 and
2). Lane 3, same as lane 1 but with lymphocytes from patient #3. Lane 4, same as lane 1, but with lymphocytes from a JBS patient with a
homozygous nonsense mutation in UBR1, previously shown to have no detectable UBR1 (null UBR1 control) [17]. Lane 5, same as a lane 1.
doi:10.1371/journal.pone.0024925.g004
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presence of Ubr1
Q1224E were slightly but reproducibly lower than
the levels of the same reporters in ubr1D cells that carried empty
vector (Fig. 4A).
Ubr1
V146L, a mimic of the missense JBS mutation in UBR1 of
patient #1 (Figs. 1B, 2A, and 3C), was apparently inactive in
conferring metabolic instability on His-bgal but exhibited a
reproducibly significant activity with Tyr-bgal (Fig. 4A). Ubr1
recognizes N-terminal His, a type-1 destabilizing residue, via its
type-1 binding site, which resides in the UBR domain, i.e., the
region of mutation in Ubr1
V146L (Fig. 1B and Fig. 3B, C). As
discussed above, the severity of perturbation of the UBR domain
by this mutation (V146L) is predicted to be lower than the one by
H160R. Thus, a parsimonious interpretation of these results is that
a functional perturbation of the UBR domain in Ubr1
V146L
abolishes (or nearly abolishes) its activity toward type-1 N-end rule
substrates but only impairs (does not abolish) its targeting of type-2
N-end rule substrates, exemplified by Tyr-bgal (Fig. 4A). The N-
terminal Tyr residue is recognized by the type-2 site of Ubr1,
located downstream of the UBR domain [16,18,19,28]. In sum, a
decreased but significant activity of Ubr1
V146L in targeting Tyr-
bgal (Fig. 4A) is consistent with a lower extent of (expected)
perturbation of the UBR domain by this mutation, in comparison
to the one in Ubr1
H160R (Fig. 3B–D).
Remarkably, the absence of detectable functional activity in
yeast Ubr1
H160R (the mimic of human UBR1 in patient #2),
versus the presence of residual activities in both yeast Ubr1
V146L
and Ubr1
Q1224E (the mimics of human UBR1 in patients #1 and
#3, respectively) (Fig. 4A), correlated with a stronger clinical
expression of JBS symptoms in patient #2, in comparison to
patients #1 and #3 (Table 1, Fig. 2, and discussion above).
Regulation of peptide import by wild-type and mutant
Ubr1 proteins
The binding of short peptides with destabilizing N-terminal
residues to the type-1/2 sites of Ubr1 (see Introduction)
allosterically activates the autoinhibited third substrate-binding
site of Ubr1 that recognizes an internal degron of Cup9, a
transcriptional repressor of roughly 50 genes [17,33,44,52,55].
Genes that are down-regulated by Cup9 include PTR2, which
encodes the transporter of di- and tripeptides [70]. The resulting
Ubr1-Cup9-Ptr2 positive-feedback circuit, in which the Ubr1-
mediated degradation of the Cup9 repressor is accelerated by
type-1/2 peptides that bind to Ubr1, allows S. cerevisiae to sense the
presence of extracellular peptides and to react by accelerating their
uptake through induction of the Ptr2 transporter [44,52,55]. A
previously characterized cell growth assay allows comparisons of
the efficacies of dipeptide import by congenic S. cerevisiae strains
[27,33,52]. In this assay, a lysine-requiring S. cerevisiae strain is
grown on plates containing either lysine (Lys) or the Lys-Ala
dipeptide as the sole source of Lys in the medium. To grow under
the latter conditions, cells must be capable of a sufficiently
efficacious dipeptide import. ubr1D S. cerevisiae carrying either a
vector plasmid or otherwise identical plasmids expressing wild-
type Ubr1 or its missense mutants Ubr1
H160R, Ubr1
V146L and
Ubr1
Q1224E, were grown in the presence of either Lys or Lys-Ala
in the medium (Fig. 4C). Whereas all examined strains grew in the
presence of Lys, only cells expressing wild-type Ubr1 grew on
plates containing Lys-Ala instead of Lys (Fig. 4C).
In a different assay for peptide import, relative levels of
induction of the peptide transporter Ptr2 were assayed by
measuring the activity of a lacZ (bgal-encoding) reporter that
was expressed from the PPTR2 promoter in ubr1D S. cerevisiae that
carried either an empty vector or otherwise identical plasmids that
expressed wild-type Ubr1 [27,28,52] or its missense mutants. In
contrast to wild-type Ubr1, which strongly induced the PPTR2-lacZ
fusion, both Ubr1
H160R and Ubr1
Q1224E mutants did not induce it
detectably, i.e., significantly above the level in the presence of
vector alone (Fig. 4B). Interestingly, the Ubr1
V146L mutant,
similarly to its reduced but still significant activity in mediating
the in vivo degradation of Tyr-bgal (Fig. 4A), exhibited a
diminished but significant activity in the PPTR2-lacZ assay (Fig. 4B).
As a part of Ubr1 tests, we also compared the levels of wild-type
and mutant Ubr1 proteins that were produced from the native
PUBR1 promoter and low copy plasmids in ubr1D S. cerevisiae (see
Materials and Methods). Cell extracts from indicated S. cerevisiae
transformants were subjected to SDS-PAGE and immunoblotting
with the previously characterized, affinity-purified antibody to
yeast Ubr1 [33]. Similar amounts of Ubr1 and its mutants were
produced in yeast transformants that had been employed in
experiments of this study, except for Ubr1
H160R, whose levels were
considerably lower than the levels of either wild-type Ubr1,
Ubr1
Q1224E or Ubr1
V146L (see Fig. 4D and its legend for details).
The Ubr1-expressing plasmids were identical save for single-
nucleotide nonsynonymous mutations in the UBR1 ORF (Fig. 1B,
C). Thus a parsimonious interpretation is that the H160R
mutation, which is expected to strongly destabilize the UBR
domain (Fig. 3D) (see discussion above), results, in turn, in a
metabolic destabilization and low steady-state levels of the
Ubr1
H160R protein (Fig. 4D).
This interpretation is strongly supported by independent
evidence, through immunoblotting-based comparisons of the
levels of human UBR1 proteins in lymphocytes of JBS patients
(Fig. 4E). Whereas the mutant UBR1
Q1102E protein of patient #3
was readily detectable in lymphocytes of this patient, no UBR1
could be detected in otherwise identical extracts from patient #2,
whose UBR1
H136R was the counterpart of yeast UBR1
H160R
(Fig. 4E). We conclude that the absence of detectable Ubr1
H160R
activity in vivo, in contrast to Ubr1
Q1224E and Ubr1
V146L (Fig. 4A,
B), stemmed, at least in part, from the accelerated in vivo
degradation of Ubr1
H160R, in addition to the likely diminished
or absent functional activity of this mutant. A precedent for a
single missense mutation that could confer a short in vivo half-life
on yeast Ubr1 was the previously characterized change of its wild-
type Tyr
277 to Ala or Glu [33].
Discussion
Mutational inactivation of human UBR1, one of the E3 Ub
ligases of the Arg/N-end rule pathway (Fig. 1A), is the cause of
Johanson-Blizzard syndrome (see Introduction) [1,2,6,17]. Previ-
ously studied cases of the typical severe expression of the syndrome
involved nonsense, frameshift or splice-site mutations of UBR1 that
were either certain or very likely to completely abolish UBR1
activity [6]. The present study of less severe JBS cases and their
association with missense mutations in one of two copies of UBR1
indicates that the relative mildness of symptoms in JBS patients #1
and #3 (Fig. 2A, C) is most likely caused by a significant residual
activity of the corresponding UBR1 mutants (Figs. 1B, C and 4A–
C).
The mechanistic cause(s) of JBS remains to be understood, in
part because all other UBR-type N-recognins, including UBR2
(which is 47% identical to UBR1 [11,34] and is expressed in
exocrine pancreas as well) are retained in JBS patients. Their cells,
therefore, still contain the Arg/N-end rule pathway. One
possibility is that UBR1, despite its strong sequelogy [63] to
UBR2, has a physiological protein substrate(s) that is unique to
UBR1. If so, a loss of UBR1 activity (for example, its total loss in
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(normally short-lived) substrate(s) and thereby mediate (or
contribute to) the broad range of JBS phenotypes, with severity
of these phenotypes determined by the levels of residual UBR1
activity in specific cell types of a JBS patient. Alternatively,
physiological substrates that are not unique to UBR1 might be
involved. Previous work has shown that S. cerevisiae Ubr1 is an
activity-limiting component of the yeast Arg/N-end rule pathway
[71]. Thus UBR1 and UBR2 may share all of JBS-relevant
physiological substrates but in the absence of UBR1 the efficacy of
targeting of such substrates by UBR2 alone might not be high
enough, particularly in some cell types. (Expression patterns of
mouse Ubr2 overlap with but are not identical to those of Ubr1
[11,34].)
It is also possible that a JBS-relevant function of UBR1 is a
previously unknown and a priori unexpected one. For example, it
was recently shown that mouse Ubr2, a strong sequelog of Ubr1
(47% identity in mice), functions to metabolically stabilize Tex19.1,
a germ cell-specific protein in mouse testis, through a direct
interaction between Ubr2 and Tex19.1 [62]. Metabolic stabiliza-
tion of Tex19.1 by Ubr2 in wild-type mouse cells is functionally
relevant, because both Tex19.1
2/2 mice and Ubr2
2/2 mice
exhibit similar phenotypes of defective spermatogenesis, and the
levels of Tex.19.1 in testis are strongly decreased in the absence of
Ubr2 [62]. It is unknown, at present, whether Ubr1 also binds to
and stabilizes Tex19.1. However, it is already clear that at least
some N-recognins not only target proteins for degradation but can
also bind to and protect specific proteins from degradation in vivo
[17,62], a circumstance that further increases the range of UBR1
mechanisms that may be relevant to JBS.
A major lacuna in the current understanding of mammalian N-
recognins is the paucity of identified physiological UBR1
substrates. At present, the known (as distinguished from putative)
substrates of mammalian UBR1 comprise largely the G-protein
regulators RGS4, RGS5 and RGS16, and the separase-produced
fragment of the Rad21 cohesin subunit (refs. [16,17,51,72] and
refs. therein). Misfolded proteins are also among physiological
substrates of UBR1 and UBR2 in mammals and Ubr1 in yeast,
although specific degrons involved remain to be identified
[57,58,59,60]. In addition, physiological substrates of S. cerevisiae
Ubr1 include Cup9 and Mgt1, a transcriptional repressor and a
DNA repair protein, respectively (see Introduction). For several
reasons [16,17], it is highly likely that mammalian UBR1 and
other eukaryotic N-recognins have a large number of physiological
substrates. Identifying such proteins (Fig. 1A), with an emphasis on
substrates that might be unique for UBR1 (as distinguished, for
example, from UBR2), should advance the mechanistic under-
standing of JBS and its multiple phenotypes.
Materials and Methods
Patients
This study was approved by the Local Ethics Committee
(University Hospital, Magdeburg, Germany), and informed
consent, in writing, was obtained from the parents/patients,
including written informed consent for publication of the present
data in biomedical journals, including PLoS One. Patients were
personally evaluated by a clinical geneticist (M.C.A, A.P.A, H.B.)
and their hospital charts were reviewed. These patients are a part
of the cohort of 35 unrelated, molecularly confirmed JBS patients
that were identified over several years. The criterion for inclusion
in this study was the presence of a missense UBR1 mutation
affecting an amino acid residue at a position conserved between
human UBR1 and S. cerevisiae Ubr1.
Mutations in UBR1
Genomic DNA was extracted from peripheral blood leukocytes
using standard methods. All 47 coding exons of the human UBR1
gene and flanking intronic regions were amplified by PCR and
subjected to bidirectional sequencing using the dye-terminator
sequencing method (BigDye Terminator v.3.1; Applied Biosys-
tems) and an automated capillary sequencer ABI 3730 Genetic
Analyzer, (Applied Biosystems, Weiterstadt, Germany), as de-
scribed previously [6].
Yeast strains, plasmids, b-galactosidase assays, and
immunoblotting
The S. cerevisiae strains used were JD52 (MATa ura3-52 his3-
D200 leu2-3,112 trp1-D63 lys2-801 ubr1D::HIS3) and JD55 (MATa
ura3-52 his3-D200 leu2-3,112 trp1-D63 lys2-801 ubr1D::HIS3) [56].
The low-copy plasmids were the previously described pRS315
(control vector) and pCH100 (pRS315-UBR1) [32,33], or the
otherwise identical pCH638 (pRS315-UBR1
H160R), pCH639
(pRS315-UBR1
Q1224E), and pCH640 (pRS315-UBR1
V146L) that
expressed Ubr1 mutants. The pCH100 plasmid contained only
one of the StuI, SpeI, MscI and MluI sites in S. cerevisiae UBR1.
Overlapping-extension PCR was used to introduce specific
mutations (V146L, H160R and Q1224E) into the UBR1 ORF.
A pair of PCR primers, OOM7/OOM8 or OCH56/OCH88
(Table 1), which flanked the region between the StuI and SpeI sites,
or between the MscI and MluI sites of UBR1, were used to
construct V146L, H160R and Q1224E UBR1 mutants. To do so,
pCH100 was employed as a PCR template, in conjunction with
specific primers (Table 1). The resulting PCR products were
digested with StuI/SpeIo rMscI/MluI and ligated into StuI/SpeI-cut
or MscI/MluI-cut pCH100, yielding the plasmids pCH638,
pCH640 and pCH639, respectively.
Standard yeast techniques and media were employed for strain
construction, transformation and growth [73,74]. Assays for b-
galactosidase (bgal) activity in S. cerevisiae extracts were carried out
as previously described [27,30,31,69], using Yeast b-Galactosidase
Assay Kit (Thermo scientific, Rockford, IL) and the manufactur-
er’s protocol. Immunoblotting of proteins that had been
fractionated by SDS-4–12% NuPAGE was carried out as
previously described, using a previously characterized, affinity-
purified antibody to S. cerevisiae Ubr1 [27,32,56]. Immunoblotting
of extracts from human lymphocytes was carried out using
antibody to human UBR1, as previously described [6].
JD55 (ubr1D) S. cerevisiae carried the plasmids pSS4 (PPTR2-LacZ)
and either pCH100 (wild-type Ubr1), pCH638 (Ubr1
H160R),
pCH639 (Ubr1
Q1224E), or pCH640 (Ubr1
V146L). Cells were grown
at 30uC in synthetic complete (SC) medium (0.17% yeast nitrogen
base, 0.5% ammonium sulfate, 2% glucose, plus a dropout mixture
of compounds required by a given auxotrophic strain) to A600 ,0.8,
followed by the measurements of bgal activity in cell extracts.
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